The formation of fistulas in Crohn's disease (CD) involves specific cellular players and processes that contribute to their development and persistence. Recent research has revealed that fibroblasts, a type of connective tissue cell, play a central role in fistula formation.
The formation of fistulas in Crohn's disease (CD) involves specific cellular players and processes that contribute to their development and persistence. Recent research has revealed that fibroblasts, a type of connective tissue cell, play a central role in fistula formation. In fistulating CD patients, a unique group of fibroblasts, termed fistula-associated stromal (FAS) fibroblasts, was identified. These cells are linked to tissue remodeling, fibrosis (scar-like tissue formation), and immune modulation through cytokine production.
Spatial mapping of fistula tracts showed that FAS fibroblasts organize in distinct layers. Closest to the fistula lumen is a proliferative zone rich in neutrophils and macrophages, surrounded by an active core of stromal fibroblasts. This is further encased by an outer quiescent zone of pro-fibrotic fibroblasts. These layers work together to sustain the fistula structure and promote its persistence.
The study highlights that common molecular pathways and cellular environments drive fistula formation across different intestinal locations. While current treatments for CD mainly target inflammation, this research emphasizes the need to address the role of fibroblasts and their abnormal activity. By targeting these cellular mechanisms, new therapies could potentially reduce fistula formation and improve outcomes for CD patients.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.